Country-wise Listing - China

To view the articles from different countries, Please click on the country name on left side countries menu.
S.NO Title & Authors Name page
1
REVERSAL OF MULTI-DRUG RESISTANCE IN MDR CANCER CELL BY 3113, A NEW DIPEPTIDOMIMETIC OF P-AMINOBENZOIC ACID
*Haiyan Wei , Jufang Yan , Wentao Liu and Chunyuan Fan
 Abstract                  View                 Download                 XML
In this study, we reported for the first time that a new compound named 3113, which is the dipeptidomimetic of p-aminobenzoic acid showed multi-drug resistance (MDR) reversal activity. In MDR cancer cells, no matter acquired or inherent, combination with 3113 enhanced doxorubicin (DXR) cytotoxicity by 8 to 10 folds, which was slightly higher than the effect of verapamil (VPL). 3113 was indicated to enhance the cytotoxicity of anticancer drugs through increasing its intracellular accumulation in a time-dependent manner. According to the result of FCM (flow cytometry), the intracellular fluorescence representing the concentration of intracellular DXR was improved by 10 folds as compared with the MDR cells without 3113. Western blotting analysis of P-glycoprotein (P-gp) confirmed that 3113 can alter P-gp expression in a time-dependent way. In conclusion, MDR reversal activity of 3113 depends on, at least in part, the inhibition of P-gp expression.
432-438
2
Role of Prior Rituximab on Outcomes of Asct in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
Li Li
 Abstract                  View                 Download                 XML
The aim of this study was to investigate the impact of prior rituximab on the subsequent results of autologous stem cell transplantation (ASCT) for relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL). The random-effect model was used with the relative risk (RR) as the measure indicator. Patients were divided into two groups according to whether rituximab was administered (R group) or not (No-R group) prior to ASCT. The meta-analyzed RR and 95% confidence interval in the R group versus the No-R group were: 0.83 (0.69,0.99), 0.84 (0.72,0.98), 0.94 (0.71,1.25) for two-, three-, five-year overall survival (OS); 0.91 (0.77,1.08), 0.85 (0.69,1.06), 0.85 (0.62,1.17) for two-, three-, and five-year progress free survival (PFS); 0.46 (0.27,0.80), 0.47 (0.29,0.76), 0.74 (0.15,3.52) for two-, three-, and five-year event free survival (EFS). The results show the treatment trend of pre-treating with first-line rituximab-containing therapy for relapsed or refractory DLBCL is more favorable than with ASCT-naive.
47-55